{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:47:15Z","timestamp":1788281235280,"version":"build-2803163510"},"reference-count":32,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We aimed to investigate the adverse drug reactions (ADRs) observed in cancer patients, the drugs causing ADRs, ADRs reporting rate, common adverse effects, drug interactions, and the drugs used to manage these adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A questionnaire about pharmacovigilance, the most common ADRs and side effects observed in oncology patients, the frequency of these ADRs, the drugs causing them, and drug interactions was administered to the volunteers in our study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Although 66 out of the 90 nurses who participated in the study reported having previously encountered an ADR, only 39 of them actually reported it. ADRs were most frequently seen once a year or more and 56% of the ADRs were life-threatening, 21% medically important and 23% resulted in hospitalization. The pharmacological groups with the most ADR reports were; Taxanes, Platinum compounds, Monoclonal antibody (Mabs), Antimetabolites, Alkylating agents, Topoisomerase inhibitors and alkaloids respectively. ADRs were specifically related to Paclitaxel, Cisplatin and Rituximab. The most common adverse effects included; redness, itching, dyspnea and tachycardia. Antihistamines and corticosteroids were most commonly used in treatment of ADRs. The drugs that interacted most with antineoplastics were antibiotics, anticonvulsants and antihypertensives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although the incidence of ADRs in cancer patients is high, the reporting rate is relatively low. ADRs associated with antineoplastic drugs are serious reactions. Identifying which drugs cause the most ADRs is crucial for prevention, monitoring, and treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251358171","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T08:18:33Z","timestamp":1752567513000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Frequency of adverse drug reactions in cancer patients: A study at the oncology department of a university hospital"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6607-836X","authenticated-orcid":false,"given":"Zeynep","family":"Erdogmus Ozgen","sequence":"first","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Dicle University, Diyarbakir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bar\u0131s","family":"Asana","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Dicle University, Diyarbakir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed Mansur","family":"Ozgen","sequence":"additional","affiliation":[{"name":"Chemotherapy Pharmacy, Oncology Hospital, School of Medicine, Dicle University, Diyarbakir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29210"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03262002"},{"key":"e_1_3_3_4_2","first-page":"386","article-title":"Prospective observational, non-randomized, parallel sequence study for assessment of adverse drug reactions due to chemotherapeutic treatment in different types of cancer patients","volume":"4","author":"Mrugank BP","year":"2013","unstructured":"Mrugank BP, Hareesha RP. Prospective observational, non-randomized, parallel sequence study for assessment of adverse drug reactions due to chemotherapeutic treatment in different types of cancer patients. Int J Pharm Sci Res 2013; 4: 386.","journal-title":"Int J Pharm Sci Res"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2193394"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.4103\/0971-5851.177015"},{"key":"e_1_3_3_7_2","first-page":"15","article-title":"Study of prescription pattern and adverse drug reactions of antineoplastic drugs in patients with breast cancer in a tertiary care teaching hospital","volume":"31","author":"Kadam RL","year":"2017","unstructured":"Kadam RL, Motghare VM, Sontakke S, et al. Study of prescription pattern and adverse drug reactions of antineoplastic drugs in patients with breast cancer in a tertiary care teaching hospital. Group (New York) 2017; 31: 15.","journal-title":"Group (New York)"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1230514"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-018-0653-5"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1148"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.31662\/jmaj.2021-0015"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0737-0"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/anae.14143"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0281-0"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/XEB.0000000000000075"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijp.IJP_544_17"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0476"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-022-03287-1"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462313000457"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0256-6"},{"key":"e_1_3_3_21_2","first-page":"3","article-title":"Identification and analysis of adverse drug reactions asso-ciated with cancer chemotherapy in hospitalized patients","volume":"6","author":"Antony A","year":"2016","unstructured":"Antony A, Joel JJ, Shetty J, et al. Identification and analysis of adverse drug reactions asso-ciated with cancer chemotherapy in hospitalized patients. Int J Pharm Pharmaceut Sci 2016; 6: 3\u20137.","journal-title":"Int J Pharm Pharmaceut Sci"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-019-00860-0"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-021-03138-5"},{"key":"e_1_3_3_24_2","first-page":"1","article-title":"Safe prescription of systemic antineoplastic treatment in oncology: integrative literature review","volume":"18","author":"Alves FV","year":"2022","unstructured":"Alves FV, Silveira RCDCP, Cruz FODAMD, et al. Safe prescription of systemic antineoplastic treatment in oncology: integrative literature review. Braz J Oncol 2022; 18: 1\u201310.","journal-title":"Braz J Oncol"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.13005\/bbra\/2477"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.18203\/2319-2003.ijbcp20230394"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12944"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-05204-2"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.808848"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-010-9410-0"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P733"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/1076029620936325"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/nop\/npv038"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251358171","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251358171","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251358171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:31:26Z","timestamp":1777689086000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251358171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":32,"alternative-id":["10.1177\/10781552251358171"],"URL":"https:\/\/doi.org\/10.1177\/10781552251358171","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"article-number":"10781552251358171"}}